Bristol-Myers Squibb Company / Turning Point Therapeutics Inc.
2022 · Acquisition/Merger · $4.1B · Complete
Announcement Sentiment
93
Strongly positive
Outcome Score
70
Largely worked — most objectives met.
Bristol-Myers Squibb acquired Turning Point Therapeutics for approximately $4.1 billion ($76.00 per share) in an all-cash tender offer, gaining repotrectinib (Augtyro), a next-generation ROS1/NTRK inhibitor with differentiated activity in ROS1-positive non-small cell lung cancer.